What's Hot
View all perspectives
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
TheDaoIndex KDAO2011
2 years 5 months ago
Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN
Richard Conway RichardPAConway
2 years 5 months ago
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
David Liew drdavidliew
2 years 5 months ago
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
Mrinalini Dey DrMiniDey
2 years 5 months ago
@Yuz6Yusof on breakthrough infections & severe #COVID in RTX treatment #EULAR2022
🦠Rate of mod/severe COVID infection comparable to pre-pandemic severe infection rate
💉High vaccination rate prevented severe disease
📊Consider #comorbidities & low IgG in risk-benefit assessment https://t.co/PGUVbHD7i2
Aurelie Najm AurelieRheumo
2 years 5 months ago
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Dr. John Cush RheumNow
2 years 5 months ago
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6
David Liew drdavidliew
2 years 5 months ago
RA & dementia - it's getting more damning
RA dementia risk: HR 1.25
from Korean nationwide data: RA n=138,592
this follows @MyasoedovaElena's data
RA systemic inflamm leading to dementia (AD, vascular)?
Need to understand if any DMARD protective
OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
Richard Conway RichardPAConway
2 years 5 months ago
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou
⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts
⭐️UIP seen in 88% of deceased patients, 56% of living
⭐️Median survival 5.3 years
@RheumNow https://t.co/tGBQ5GBlVg
TheDaoIndex KDAO2011
2 years 5 months ago
Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q
Richard Conway RichardPAConway
2 years 5 months ago
Mestre-Torres et al. Features at GCA diagnosis that predict permanent vision loss. Age>75, jaw claudication, amaurosis fugax increase risk. Systemic symptoms decrease risk @RheumNow #EULAR2022 POS0271 https://t.co/FPC9R1v8S3
Aurelie Najm AurelieRheumo
2 years 5 months ago
FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04)
⚡️Detects metabolic activity and tissular inflammation
⚡️Correlates with MRI changes in PsA
⚡️Is associated
w/ progression of joint damage
⚡️Is sensitive to change
An exciting new imaging modality!
@RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 OP0273
Difficult to treat RA (D2TRA):
⭐️Lower socioeconomic treatment
⭐️RF positivity
⭐️Higher inflammatory markers
⭐️ILD
⭐️Lower proportion on MTX, better response to JAKi and RTX
@RheumNow
David Liew drdavidliew
2 years 5 months ago
Was ORAL Surveillance really a surprise?
Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE)
Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa
ORAL Surveillance was worse, but clues were always there
OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc
Poster Hall